Current HIV/AIDS Reports

, Volume 15, Issue 2, pp 113–119 | Cite as

Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned

  • April M. Young
  • Abby E. Rudolph
  • Jennifer R. Havens
The Global Epidemic (SH Vermund, Section Editor)
  • 126 Downloads
Part of the following topical collections:
  1. Topical Collection on The Global Epidemic

Abstract

Purpose of Review

The purpose of this paper is to provide a thorough overview of methods used for recruitment, network data collection, and network data management in a network-based study of rural people who use drugs (PWUD) and to offer methodological recommendations for future research on rural drug use.

Recent Findings

The Social Networks among Appalachian People (SNAP) study recruited a cohort of 503 rural PWUD via respondent-driven sampling (RDS) and has retained more than 80% of eligible participants over 7–9 years. SNAP has yielded important methodological insights, including that (1) RDS referral was non-random and disproportionately involved kin and (2) interviewer-administered questionnaires were successful in eliciting accurate name and age information about network members.

Summary

The SNAP experience suggests that RDS was a successful recruitment strategy for rural PWUD and questionnaires administered by community-based interviewers in the context of a Certificate of Confidentiality could elicit detailed data on PWUD risk networks.

Keywords

Social networks Rural Substance use HIV Hepatitis C Appalachia Opioid 

Notes

Acknowledgments

We would like to acknowledge the community-based study staff for the critical role they have played in the success of the project.

Compliance with Ethical Standards

Conflict of Interest

April M. Young reports grants from National Institute on Drug Abuse and from National Institute of Mental Health.

Abby E. Rudolph reports a grant from National Institute on Drug Abuse (K01 DA033879).

Jennifer R. Havens declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Appalachian Regional Commission. Subregions in Appalachia. 2009 [cited 2017 October 27]; Available from: https://www.arc.gov/research/sourceandmethodologygeography.asp.
  2. 2.
    Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Suryaprasad AG, White JZ, Xu F, Eichler B-A, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59(10):1411–9.CrossRefPubMedGoogle Scholar
  5. 5.
    PDA I, Cecil G. Sheps Center for Health Services Research, Appalachian Regional Commission. Creating a culture of health in Appalachia: disparities and bright spots. August 2017.Google Scholar
  6. 6.
    Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr (1999). 2016;73(3):323–31.CrossRefGoogle Scholar
  7. 7.
    Zhang Z, Infante A, Meit M, English N, Dunn M, Bowers K. An analysis of mental health and substance abuse disparities & access to treatment services in the Appalachian region. Final report Washington: Appalachian Regional Commission. 2008.Google Scholar
  8. 8.
    Appalachian Regional Commission. Health care costs and access disparities in Appalachia. Washington, DC 2012.Google Scholar
  9. 9.
    Young A, Jonas A, Mullins U, Halgin DS, Havens J. Network structure and the risk for HIV transmission among rural drug users. AIDS Behav. 2013;17(7):2341–51.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Young AM, Jonas AB, Havens JR. Social networks and HCV viraemia in anti-HCV-positive rural drug users. Epidemiol Infect. 2013;141(02):402–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Jonas A, Young AM, Oser CB, Leukefeld C, Havens JR. OxyContin® as currency: OxyContin® use and increased social capital among rural Appalachian drug users. Soc Sci Med. 2012;74(10):1602–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Havens J, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rudolph AE, Young AM, Havens JR. Examing the social context of injection drug use: social proximity vs. geographic proximity to others who inject drugs. Am J Epidemiol. 2017;186:970–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2011;107:587–96.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Havens JR, Oser CB, Knudsen HK, Lofwall M, Stoops WW, Walsh SL, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011;115(1–2):107–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Young AM, Larian N, Havens JR. Gender differences in circumstances surrounding first injection experience of rural injection drug users in the United States. Drug Alcohol Depend. 2014;134:401–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Hofmeister MG, Havens JR, Young AM. Silence surrounding hepatitis C status in risk relationships among rural people who use drugs. J Prim Prev. 2017;38(5):481–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Young AM, Halgin DS, Havens JR. Relationship-level analysis of drug users’ anticipated changes in risk behavior following HIV vaccination. AIDS care. 2015;27(8):1000–04.Google Scholar
  19. 19.
    Young AM, Halgin DS, DiClemente RJ, Sterk CE, Havens JR. Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users’ anticipated risk compensation. PLoS One. 2014;9(7):e101047.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Young AM, DiClemente RJ, Halgin DS, Sterk CE, Havens JR. Drug users’ willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis. AIDS Behav. 2014;18(9):1753–63.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Young AM, Stephens DB, Khaleel HA, Havens JR. Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment. Contemp Clin Trials. 2015;41:9–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Stephens DB, Young AM, Mullins UL, Havens JR. Correlates to seroprevalent herpes simplex virus type 2 among rural Appalachian drug users. J Med Virol. 2016;88(3):512–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Smith RV, Young AM, Mullins UL, Havens JR. Individual and network correlates of antisocial personality disorder among rural nonmedical prescription opioid users. J Rural Health. 2017;33(2):198–207.CrossRefPubMedGoogle Scholar
  24. 24.
    Rudolph AE, Young AM, Havens JR. A rural/urban comparison of privacy and confidentiality concerns associated with providing sensitive location information in epidemiologic research involving persons who use drugs. Addict Behav. 2017;74:106–11.CrossRefPubMedGoogle Scholar
  25. 25.
    Young AM, Rudolph AE, Su AE, King L, Jent S, Havens JR. Accuracy of name and age data provided about network members in a social network study of people who use drugs: implications for constructing sociometric networks. Ann Epidemiol. 2016;26(11):802–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Young AM, Rudolph AE, Quillen D, Havens JR. Spatial, temporal and relational patterns in respondent-driven sampling: evidence from a social network study of rural drug users. J Epidemiol Community Health. 2014;68(8):792–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    U.S. Census Bureau. Kentucky Quick Facts: Perry County 2010. 2011 [updated June 03, 2011; cited 2011 June 17, 2011]; Available from: http://quickfacts.census.gov/qfd/states/21/21193.html.
  28. 28.
    Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl 2):S67–72.CrossRefPubMedGoogle Scholar
  29. 29.
    Malekinejad M, Johnston LG, Kendall C, Kerr LRFS, Rifkin MR, Rutherford GW. Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behav. 2008;12(Suppl 1):S105–S30.CrossRefPubMedGoogle Scholar
  30. 30.
    Lu X. Respondent-driven sampling: theory, limitations & improvements. Stockholm: Karolinska Institutet; 2013.Google Scholar
  31. 31.
    Wang J, Falck RS, Li L, Rahman A, Carlson RG. Respondent-driven sampling in the recruitment of illicit stimulant drug users in a rural setting: findings and technical issues. Addict Behav. 2007;32(5):924–37.CrossRefPubMedGoogle Scholar
  32. 32.
    Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.CrossRefGoogle Scholar
  33. 33.
    Heckathorn D. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49(1):11–34.CrossRefGoogle Scholar
  34. 34.
    McCreesh N, Frost S, Seeley J, Katongole J, Tarsh MN, Ndunguse R, et al. Evaluation of respondent-driven sampling. Epidemiology. 2012;23(1):138–47.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Wang J, Carlson RG, Falck RS, Siegal HA, Rahman A, Li L. Respondent-driven sampling to recruit MDMA users: a methodological assessment. Drug Alcohol Depend. 2005;78(2):147–57.CrossRefPubMedGoogle Scholar
  36. 36.
    Rudolph AE, Crawford ND, Latkin C, Heimer R, Benjamin EO, Jones KC, et al. Subpopulations of illicit drug users reached by targeted street outreach and respondent-driven sampling strategies: implications for research and public health practice. Ann Epidemiol. 2011;21(4):280–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ramirez-Valles J, Heckathorn DD, Vazquez R, Diaz RM, Campbell RT. From networks to populations: the development and application of respondent-driven sampling among IDUs and Latino gay men. AIDS Behav. 2005;9(4):387–402.CrossRefPubMedGoogle Scholar
  38. 38.
    McCreesh N, Johnston LG, Copas A, Sonnenberg P, Seeley J, Hayes RJ, et al. Evaluation of the role of location and distance in recruitment in respondent-driven sampling. Int J Health Geogr. 2011;10:56.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Qiu P, Yang Y, Ma X, Wu F, Yuan P, Liu Q, et al. Respondent-driven sampling to recruit in-country migrant workers in China: a methodological assessment. Scand J Public Health. 2012;40(1):92–101.CrossRefPubMedGoogle Scholar
  40. 40.
    Burt RD, Hagan H, Sabin K, Thiede H. Evaluating respondent-driven sampling in a major metropolitan area: comparing injection drug users in the 2005 Seattle area national HIV behavioral surveillance system survey with participants in the RAVEN and Kiwi studies. Ann Epidemiol. 2010;20(2):159–67.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nova Research Company. Questionnaire Development System Computer Assisted Personal Interviewing. 2017.Google Scholar
  42. 42.
    Needle R, Fisher DG, Weatherby N, Chitwood D, Brown B, Cesari H, et al. Reliability of self-reported HIV risk behaviors of drug users. Psychol Addict Behav. 1995;9(4):242–50.CrossRefGoogle Scholar
  43. 43.
    Cacciola JS, Alterman AI, McLellan AT, Lin Y-T, Lynch KG. Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug Alcohol Depend. 2007;87(2):297–302.CrossRefPubMedGoogle Scholar
  44. 44.
    Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.PubMedGoogle Scholar
  45. 45.
    Tourangeau R, Smith TW. Asking sensitive questions: the impact of data collection mode, question format, and question context. Public opinion quarterly. 1996;60(2):275–304.CrossRefGoogle Scholar
  46. 46.
    Microsoft Excel. Fuzzy Lookup Add-In. 1.0.0.0 ed2011.Google Scholar
  47. 47.
    Hopkins C, Young AM. SPIDER: semi-automated processing of interconnected dyads using entity resolution. Cambridge: Charles River Analytics and University of Kentucky; 2017.Google Scholar
  48. 48.
    Friedman SR, Neagius A, Jose B, Curtis R, Goldstein M, Ildefonso G, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Weeks MR, Clair S, Borgatti SP, Radda K, Schensul JJ. Social networks of drug users in high-risk sites: finding the connections. AIDS Behav. 2002;6(2):193–206.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • April M. Young
    • 1
    • 2
  • Abby E. Rudolph
    • 3
  • Jennifer R. Havens
    • 2
  1. 1.Department of EpidemiologyUniversity of Kentucky College of Public HealthLexingtonUSA
  2. 2.Center on Drug and Alcohol ResearchUniversity of Kentucky College of MedicineLexingtonUSA
  3. 3.Department of EpidemiologyBoston University School of Public HealthBostonUSA

Personalised recommendations